Reply: Weekly Fluconazole for Preventing Mucosal Candidiasis in HIV Infection

  1. Paula Schuman, MD, MPH; and
  2. Jack D. Sobel, MD
  1. Wayne State University School of Medicine; Detroit, MI 48201

    The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

    •Include no more than 300 words of text, three authors, and five references

    •Type with double-spacing

    •Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

    Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

    Annals welcomes electronically submitted letters.

    IN RESPONSE:

    We share Dr. Baily's concern about the potential for the emergence of resistant candidiasis in patients receiving fluconazole prophylaxis. Although women in the treatment group of our study did not have more episodes of resistant candidiasis than those in the placebo group, we do not, as Dr. Baily says, recommend “widespread use of this regimen.” We suggest that prophylaxis be considered as a therapeutic option only in persons at high risk for recurrence of mucosal candidiasis. Thirty percent of women studied reported two or more episodes of vaginal candidiasis in the year before study entry and were more likely to have new episodes during the study than were women who reported fewer episodes of vaginitis. Women who find these infections extremely troublesome, particularly those who have had four or more documented episodes of vaginal candidiasis in the previous year, should be made aware of the potential risks and benefits of antifungal prophylaxis.

    Paula Schuman, MD, MPH

    Jack D. Sobel, MD

    Wayne State University School of Medicine; Detroit, MI 48201

    « Previous | Next Article »Table of Contents

    Navigate This Article

    1. Top